Department of Gastroenterology, Ege University School of Medicine, İzmir, Turkey.
Department of Gastroenterology, University of Health Sciences, Ankara Etlik City Hospital, Ankara, Turkey.
BMC Gastroenterol. 2023 Nov 28;23(1):414. doi: 10.1186/s12876-023-03042-5.
There are different therapeutic approaches for biliary strictures and reducing portal hypertension in patients with symptomatic portal cavernoma cholangiopathy (PCC). Endoscopic treatment includes endoscopic biliary sphincterotomy (EST), dilation of stricture with a biliary balloon, placement of plastic stent(s) and stone extraction. Fully covered self-expandable metal stent (FCSEMS) is placed as a rescuer in case of haemobilia seen after EST, dilation of stricture and removal of plastic stent rather than the stricture treatment itself. In this retrospective observational study, we sought to assess the clinical outcomes of FCSEMS as the initial treatment for PCC-related biliary strictures.
Twelve symptomatic patients with PCC both clinically and radiologically between July 2009 and February 2019 were examined. Magnetic resonance cholangiopancreatography (MRCP) and cholangiography were employed as the diagnostic imaging methods. Chandra-Sarin classification was used to distinguish between biliary abnormalities in terms of localization. Llop classification was used to group biliary abnormalities associated with PCC. Endoscopic partial sphincterotomy was performed in all the patients. If patients with dominant strictures 6-8-mm balloon dilation was first performed. This was followed by removal of the stones if exist. Finally, FCSEMS placed. The stents were removed 6-12 weeks later.
The mean age of the patients was 40.9 ± 10.3 years, and 91.6% of the patients were male. Majority of the patients (n = 9) were noncirrhotic. Endoscopic retrograde cholangiopancreatography (ERCP) findings showed that 11 of the 12 patients were Chandra Type I and one was Chandra Type IIIa. All the 12 patients were Llop Grade 3. All patients had biliary involvement in the form of strictures. Stent placement was successful in all patients. FCSEMSs were retained for a median period of 45 days (30-60). Seven (58.3%) patients developed acute cholecystitis. There was no occurrence of bleeding or other complications associated with FCSEMS replacement or removal. All patients were asymptomatic during median 3 years (1-10) follow up period.
FCSEMS placement is an effective method in biliary strictures in case of PCC. Acute cholecystitis is encountered frequently after FCSEMS, but majority of patients respond to the medical treatment. Patients should be followed in terms of the relapse of biliary strictures.
对于有症状的门静脉海绵样变性相关胆系狭窄和降低门静脉高压的患者,有不同的治疗方法。内镜治疗包括内镜下括约肌切开术(EST)、球囊扩张狭窄、放置塑料支架和取石。在 EST、狭窄扩张和塑料支架取出后出现胆血征的情况下,作为抢救措施,放置全覆膜自膨式金属支架(FCSEMS),而不是狭窄本身的治疗。在这项回顾性观察研究中,我们旨在评估 FCSEMS 作为 PCC 相关胆系狭窄初始治疗的临床效果。
2009 年 7 月至 2019 年 2 月,我们对 12 例有症状的 PCC 患者进行了检查,这些患者均有临床和影像学表现。磁共振胆胰管成像(MRCP)和胆管造影术被用作诊断成像方法。Chandra-Sarin 分类用于根据定位区分胆系异常。Llop 分类用于分组与 PCC 相关的胆系异常。所有患者均行内镜下部分括约肌切开术。如果存在主导性狭窄(6-8mm),首先进行球囊扩张。如果存在结石,则进行取石。最后,放置 FCSEMS。6-12 周后取出支架。
患者的平均年龄为 40.9±10.3 岁,91.6%的患者为男性。大多数患者(n=9)是非肝硬化患者。内镜逆行胰胆管造影(ERCP)检查发现,12 例患者中有 11 例为 Chandra Ⅰ型,1 例为 Chandra Ⅲa 型。所有 12 例患者均为 Llop Ⅲ级。所有患者均有胆管狭窄。所有患者的支架放置均成功。FCSEMS 的中位留置时间为 45 天(30-60 天)。7(58.3%)例患者发生急性胆囊炎。在 FCSEMS 更换或取出过程中未发生出血或其他并发症。所有患者在中位 3 年(1-10 年)随访期间均无症状。
在 PCC 的情况下,FCSEMS 放置是治疗胆系狭窄的有效方法。FCSEMS 后常发生急性胆囊炎,但大多数患者对药物治疗有反应。应注意患者胆系狭窄的复发情况。